What are the differences between torasemide and furosemide?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 5, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Torasemide and Furosemide: Key Differences

Both torasemide and furosemide are loop diuretics with equivalent clinical efficacy for heart failure management, but torasemide offers superior oral bioavailability (80% vs 64%), longer duration of action (12-16 hours vs 6-8 hours), and once-daily dosing convenience, though these pharmacokinetic advantages do not translate into improved mortality or hospitalization outcomes. 1, 2, 3

Pharmacokinetic Differences

Bioavailability and Absorption

  • Torasemide: ~80% oral bioavailability with minimal first-pass metabolism, can be taken without regard to meals 4
  • Furosemide: 60-64% oral bioavailability with significant first-pass metabolism, absorption affected by food 3
  • Clinical implication: Oral and IV doses of torasemide are therapeutically equivalent, while furosemide requires dose adjustment when switching routes

Duration of Action

  • Torasemide: 12-16 hours of diuretic effect 2
  • Furosemide: 6-8 hours of diuretic effect 2, 3
  • Clinical implication: Torasemide allows once-daily dosing, potentially improving adherence

Elimination

  • Torasemide: 80% hepatic, 20% renal elimination; half-life ~3.5 hours 4
  • Furosemide: Predominantly renal excretion as unchanged drug; half-life ~2 hours 3

Dose Equivalence

The appropriate dose conversion is approximately 40 mg furosemide = 10 mg torasemide (4:1 ratio). 5

Critical caveat: The commonly used 2:1 conversion (20 mg furosemide = 10 mg torasemide) results in excessive natriuresis with torasemide, leading to greater neurohormonal activation (increased renin, aldosterone, norepinephrine) and kidney dysfunction without improving fluid status 5. This dosing error may explain variable clinical experiences with torasemide.

Clinical Outcomes: The TRANSFORM-HF Evidence

The landmark TRANSFORM-HF trial (2024) definitively showed no difference in 12-month all-cause mortality between torasemide and furosemide in outpatients after heart failure hospitalization. 1

What Torasemide Does Better:

  • Reduced heart failure hospitalizations (RR 0.60) 6
  • Reduced cardiovascular hospitalizations (RR 0.72) 6
  • Improved left ventricular ejection fraction (mean difference +4.51%) 6
  • Better quality of life scores and reduced daily activity restrictions 7
  • Fewer urination episodes and less urgency 7

What Shows No Difference:

  • All-cause mortality 1, 6
  • All-cause hospitalizations 6
  • NYHA class improvement 6
  • Kansas City Cardiomyopathy Questionnaire scores at 12 months 8

Safety Concerns with Torasemide:

  • Increased acute kidney injury risk (HR 1.12) when compared head-to-head 9
  • Greater neurohormonal activation when dosed at 2:1 equivalence 5
  • No difference in hypokalemia or hypovolemia 9

Practical Considerations

Potassium Sparing Effect

Torasemide demonstrates more potassium-sparing properties than furosemide at equivalent natriuretic doses 10, though this did not translate to clinically significant differences in hypokalemia rates in large trials 9.

Diuretic Resistance

Both drugs face similar ceiling effects once maximum tubular delivery is achieved 1. The mechanistic substudy showed torasemide actually had lower kidney bioavailability (17.1% vs 24.8%) and shorter duration of kidney drug delivery than furosemide 5, contradicting theoretical advantages.

Guideline Recommendations

Current ACC/AHA/HFSA guidelines (2022) list both drugs as acceptable loop diuretics without preferential recommendation, noting that some patients may respond more favorably to torasemide or bumetanide due to increased oral bioavailability 2. The guidelines emphasize using the lowest dose possible to maintain euvolemia, combined with guideline-directed medical therapy.

Clinical Bottom Line

Choose furosemide as first-line therapy given equivalent mortality outcomes, lower cost, greater clinical familiarity, and lower acute kidney injury risk. Consider switching to torasemide in patients with:

  • Poor adherence requiring once-daily dosing
  • Recurrent heart failure hospitalizations despite optimal furosemide dosing
  • Suspected malabsorption issues affecting furosemide bioavailability

When switching, use a 4:1 dose equivalence (40 mg furosemide = 10 mg torasemide) to avoid excessive diuresis and neurohormonal activation 5. Monitor renal function closely after switching, as acute kidney injury risk increases 9.

Critical pitfall: Higher doses of either loop diuretic independently predict worse outcomes (mortality HR 1.40-1.74 for highest dose tertiles) 8, reflecting disease severity and sodium avidity rather than drug toxicity. This underscores that loop diuretics relieve symptoms but do not modify disease progression—they must always be combined with mortality-reducing therapies (ARNI, beta-blockers, MRAs, SGLT2 inhibitors) 1, 2.

Related Questions

In a patient with chronic heart failure who was switched from furosemide (Lasix) 20 mg to torsemide 10 mg and now has weight gain, what is the next step in management?
Is torsemide superior to furosemide (Lasix)?
What oral torsemide dose is equivalent to 80 mg intravenous furosemide in an adult with normal renal function?
When should torsemide be preferred over furosemide as the first‑line loop diuretic, and what are the appropriate dosing and monitoring recommendations for an adult with heart‑failure or volume‑overload?
For a patient not responding to furosemide 60 mg daily, what initial oral torsemide dose should be started?
How should I evaluate and manage a female patient with persistently elevated hematocrit, red blood cell count, and hemoglobin for two years?
What is Kemadrin (procyclidine hydrochloride) and how is it used?
What diet and exercise regimen should a 70‑kg perimenopausal woman with muscle hypotonia and hyperlordosis follow to safely lose about 10 kg and improve core muscle tone?
In a 75-year-old man on dabigatran who collapsed, struck the back of his head, and now has severe back pain aggravated by movement, breathing, and head motion, what is the appropriate work‑up?
In a 75-year-old man on dabigatran who fell, struck the back of his head, and now has severe back pain worsened by movement, should cardiac troponin and D-dimer be ordered?
What are the indications for pneumococcal vaccination in adults, including age thresholds and specific risk factors?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.